BlueCrest Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

BlueCrest Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.41M	Buy	+40,500	New	+$5.48M	0.21%	84

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BlueCrest Capital Management's XBI Position: Q2 2026 in Review

BlueCrest Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 1,169 shares worth $185K. The stake represents 0.01% of the portfolio and ranks #281 among its holdings. This is a return to the name: BlueCrest Capital Management previously reported a position in XBI as recently as Q4 2024.

BlueCrest Capital Management first reported a position in XBI in Q2 2017 and has held it in 6 quarters since. The position peaked at $138M in Q4 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

BlueCrest Capital Management held 1,169 shares of State Street SPDR S&P Biotech ETF worth $185K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new BlueCrest Capital Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of BlueCrest Capital Management's portfolio in Q2 2026, its #281 holding.
BlueCrest Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 6 quarters since.
BlueCrest Capital Management's State Street SPDR S&P Biotech ETF position peaked at $138M in Q4 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on BlueCrest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.